

Drugs and Therapeutics (D & T) Committee

Meeting Results July 13, 2023

Drug Name	Review Type	Committee Recommendation	Preferred Status – Final Determination
AUVI-Q	New Drug Initial Review	Preferred for infants	Preferred all strengths
Carbaglu	New Drug Initial Review	Non-Preferred	Non-Preferred
Orserdu	New Drug Initial Review	Preferred	Preferred

Sickle Cell Disease Agents			
Drug Name	PDL Status		
Adakveo Inj			Non-preferred
Endari Powder packets	Preferred		
Droxia Capsules	Preferred		
Hydrea Capsules			Non-preferred
Hydroxyurea Capules	Preferred		
Siklos Tablets			Non-preferred
Oxbryta Tablets			Non-preferred

Please Note: Drug Status changes are noted in [Blue](#)

The minutes reflecting these D&T Advisory Board actions are contained in draft minutes, yet to be approved at the next board meeting. Following that, this post will be updated only if there are amendments to those minutes.